Geneva, July 14 -- International Clinical Trials Registry received information related to the study (NCT07051031) titled 'COVID-19 Reactogenicity' on July 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Marcel Curlin
Condition:
Compare Post Vaccination Reactions
Intervention:
Drug: Nuvaxovid (NVX-CoV2705)
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: October 1, 2025
Target Sample Size: 1000
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07051031
Publishe...